Eli Lilly’s existing October 2024 technology evaluation agreement with Peptron remains strictly limited to joint research on applying SmartDepot microsphere formulations to Lilly’s peptide candidates, including GLP-1 agents, without granting commercial rights or obligating a licensing deal. The non-binding pact, extended through October 7, 2026, permits Lilly to exit with 30 days’ notice and has produced only ongoing in-vivo studies plus scope expansion into CNS indications rather than a technology transfer announcement. Lilly’s parallel pursuit of alternative long-acting platforms, such as Camurus’ FluidCrystal, alongside the absence of any confirmed commercial licensing progress in recent months, has reinforced trader consensus around the elevated “No” probability.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% tsansa
$11,414 Vol.
$11,414 Vol.
Oct 7, 2026
13% tsansa
$11,414 Vol.
$11,414 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 technology evaluation agreement with Peptron remains strictly limited to joint research on applying SmartDepot microsphere formulations to Lilly’s peptide candidates, including GLP-1 agents, without granting commercial rights or obligating a licensing deal. The non-binding pact, extended through October 7, 2026, permits Lilly to exit with 30 days’ notice and has produced only ongoing in-vivo studies plus scope expansion into CNS indications rather than a technology transfer announcement. Lilly’s parallel pursuit of alternative long-acting platforms, such as Camurus’ FluidCrystal, alongside the absence of any confirmed commercial licensing progress in recent months, has reinforced trader consensus around the elevated “No” probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Binuksan ang Market: May 5, 2026, 8:02 PM ET
Volume
$11,414Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 technology evaluation agreement with Peptron remains strictly limited to joint research on applying SmartDepot microsphere formulations to Lilly’s peptide candidates, including GLP-1 agents, without granting commercial rights or obligating a licensing deal. The non-binding pact, extended through October 7, 2026, permits Lilly to exit with 30 days’ notice and has produced only ongoing in-vivo studies plus scope expansion into CNS indications rather than a technology transfer announcement. Lilly’s parallel pursuit of alternative long-acting platforms, such as Camurus’ FluidCrystal, alongside the absence of any confirmed commercial licensing progress in recent months, has reinforced trader consensus around the elevated “No” probability.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 technology evaluation agreement with Peptron remains strictly limited to joint research on applying SmartDepot microsphere formulations to Lilly’s peptide candidates, including GLP-1 agents, without granting commercial rights or obligating a licensing deal. The non-binding pact, extended through October 7, 2026, permits Lilly to exit with 30 days’ notice and has produced only ongoing in-vivo studies plus scope expansion into CNS indications rather than a technology transfer announcement. Lilly’s parallel pursuit of alternative long-acting platforms, such as Camurus’ FluidCrystal, alongside the absence of any confirmed commercial licensing progress in recent months, has reinforced trader consensus around the elevated “No” probability.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong